Peer mentorship to improve self-management of hip and knee osteoarthritis : A randomised feasibility trial by Anderson, Anna et al.
This is a repository copy of Peer mentorship to improve self-management of hip and knee 
osteoarthritis : A randomised feasibility trial.




Anderson, Anna, Lavender, Elizabeth, Dusabe-Richards, Esther et al. (7 more authors) 
(2021) Peer mentorship to improve self-management of hip and knee osteoarthritis : A 





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1Anderson AM, et al. BMJ Open 2021;11:e045389. doi:10.1136/bmjopen-2020-045389
Open access 
Peer mentorship to improve self- 
management of hip and knee 
osteoarthritis: a randomised 
feasibility trial
Anna M Anderson   ,1,2 Elizabeth C Lavender,1 Esther Dusabe- Richards,1 
Teumzghi F Mebrahtu   ,1 Linda McGowan,1 Philip G Conaghan   ,2 
Sarah R Kingsbury,2 Gerry Richardson,3,4 Deborah Antcliff,1,5 Gretl A McHugh1
To cite: Anderson AM, 
Lavender EC, Dusabe- 
Richards E, et al.  Peer 
mentorship to improve self- 
management of hip and knee 
osteoarthritis: a randomised 
feasibility trial. BMJ Open 
2021;11:e045389. doi:10.1136/
bmjopen-2020-045389
 ► Prepublication history and 
additional supplemental material 
for this paper are available 
online. To view these files, 
please visit the journal online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2020- 
045389).
Received 29 September 2020
Accepted 04 July 2021
1School of Healthcare, University 
of Leeds, Leeds, UK
2Leeds Institute of Rheumatic 
and Musculoskeletal Medicine 
and NIHR Leeds Biomedical 
Research Centre, University of 
Leeds, Leeds, UK
3Centre for Health Economics, 
University of York, York, UK
4NIHR Research Design Service 
for Yorkshire and the Humber, 
York, UK
5Physiotherapy Department, 
Bury Care Organisation, 
Northern Care Alliance NHS 
Group, Bury, UK
Correspondence to
Anna M Anderson;  
 A. Anderson@ leeds. ac. uk
Original research
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
Objective To determine the feasibility of conducting a 
randomised controlled trial (RCT) of a peer mentorship 
intervention to improve self- management of osteoarthritis 
(OA).
Design Six- month parallel group non- blinded randomised 
feasibility trial.
Setting One secondary care and one primary care UK 
National Health Service Trust.
Participants Fifty adults aged ≥55 years old with hip and/
or knee OA.
Interventions Participants were allocated 1:1 to the 
intervention or control group using an online randomisation 
service. Intervention group participants received usual care 
(information resources) and up to eight community- based 
self- management support sessions delivered by a peer 
mentor (trained volunteer with hip and/or knee OA). Control 
group participants received usual care only.
Outcome measures Key feasibility outcomes were 
participant and peer mentor recruitment and attrition, 
intervention completion and the sample size required for 
a definitive RCT. Based on these feasibility outcomes, four 
success criteria for proceeding to a definitive RCT were 
prespecified. Patient- reported outcomes were collected via 
questionnaires at baseline, 8 weeks and 6 months.
Results Ninety- six individuals were screened, 65 were 
eligible and 50 were randomised (25 per group). Of the 
24 participants who commenced the intervention, 20 
completed it. Four participants did not complete the 
6- month questionnaire. Twenty- one individuals were 
eligible for the peer mentor role, 15 were trained and 5 
withdrew prior to being matched with a participant. No 
intervention- related harms occurred. Allowing for 20% 
attrition, the sample size required for a definitive RCT was 
calculated as 170 participants. The intervention group 
showed improvements in self- management compared with 
the control group.
Conclusions The feasibility outcomes achieved the 
prespecified criteria for proceeding to an RCT. The 
exploratory analyses suggest peer mentorship may 
improve OA self- management. An RCT of the OA peer 
mentorship intervention is therefore warranted with minor 
modifications to the intervention and trial procedures.
Trial registration number ISRCTN:50675542.
INTRODUCTION
Osteoarthritis (OA) is one of the most prev-
alent musculoskeletal conditions, with hip 
and knee OA affecting over 300 million indi-
viduals worldwide.1 Furthermore, the preva-
lence of OA is increasing due to the ageing 
population and rising obesity levels.2 Individ-
uals with OA often experience severe pain, 
impaired function and reduced quality of 
life.3 OA can have a profound psychosocial 
impact4 and results in substantial economic 
burden.5
National and international guidelines 
emphasise that patient education, self- 
management strategies and exercise are 
core elements for managing OA.6 However, 
implementation of OA guidelines is currently 
poor.7 Patients report receiving insufficient 
information about OA management8 and 
having a limited understanding of the condi-
tion.4 9 This negatively impacts patients’ 
Strengths and limitations of this study
 ► This randomised feasibility trial is the first study to 
develop a novel peer mentorship intervention specif-
ically focused on improving self- management of hip 
and knee osteoarthritis (OA).
 ► Extensive patient and public involvement ensured 
the intervention and trial procedures were tailored 
to the needs of individuals with OA.
 ► A comprehensive range of feasibility outcomes were 
assessed, providing valuable information for design-
ing a future definitive randomised controlled trial.
 ► Validated patient- reported outcome measures were 
administered; however, the results must be inter-
preted cautiously because the trial was not powered 
to detect statistically significant differences.
 ► A key limitation was that the majority of participants 
were recruited through a physiotherapy service and 
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health behaviours.4 9 A need for tailored interventions 
to support OA self- management has therefore been 
highlighted.10
Peer support interventions are an established approach 
for supporting chronic condition self- management.11 12 
Various peer support models have been described, such as 
peer- led group programmes and peer mentorship.13 The 
latter involves a trained individual with a particular health 
condition (the ‘peer mentor’) providing one- to- one 
support to another individual with the same condition.13 
This approach is likely to be particularly valuable for indi-
viduals with OA due to the heterogeneous nature of the 
condition, which means tailored support is crucial.10 14
Previous studies have highlighted the value of OA 
interventions incorporating peer support.15 However, 
no previous studies have explored an OA peer mentor-
ship intervention. Although such an intervention offers 
multiple potential benefits, peer mentorship interven-
tions can present feasibility/acceptability issues, such as 
high peer mentor attrition.16 Therefore, this feasibility 
trial aimed to develop and trial a peer mentorship inter-
vention to improve OA self- management. Its key objec-
tives were to determine the feasibility of conducting 
a randomised controlled trial (RCT) of the OA peer 
mentorship intervention in terms of: the feasibility/
acceptability of the intervention and trial procedures; 
participant recruitment and retention; questionnaire 
completion rates; generating the sample size required 
for a definitive RCT; and estimating the intervention 
costs. Additionally, the potential impact of the interven-
tion on patient- reported outcomes and resource use was 
explored.
METHODS
This was a 6- month parallel group randomised feasibility 
trial. A nested qualitative study was included (reported 
elsewhere). The trial was prospectively registered and 
conducted between 1 September 2017 and 16 February 
2020. The trial is reported according to the CONSORT 
2010 extension for randomised pilot and feasibility 
trials17 (online supplemental tables 1 and 2). The devel-
opment and feasibility testing of the OA peer mentor-
ship intervention was guided by the Medical Research 
Council guidance on developing and evaluating complex 
interventions.18
Trial procedures and participants
Recruitment and consent
Potential participants were identified from rheumatology 
and orthopaedic clinics of one secondary care National 
Health Service (NHS) Trust and physiotherapy clinics 
and electronic records of one primary care NHS Trust. 
Both are large Trusts in Northern England. The initial 
approach was made via clinical staff during clinic appoint-
ments or through an invitation letter. Individuals inter-
ested in participating were provided with further details 
about the trial and screened for eligibility by a researcher 
at their clinic appointment or via telephone.
All participants provided written informed consent at 
their clinic appointment or during a baseline visit from 
a researcher. The latter took place in the participant’s 
home or another private location of the participant’s 
choice.
Eligibility criteria
Inclusion criteria were: (1) aged ≥55 years old and (2) 
clinician- confirmed diagnosis of hip and/or knee OA.19 
Exclusion criteria were: (1) presence of inflammatory 
arthritis (including gout and rheumatoid arthritis), (2) 
serious health conditions that would prevent participa-
tion and (3) listed for hip/knee replacement.
Sample size
Recommendations for pilot studies suggest 20 partici-
pants per arm is acceptable assuming at worst a small 
effect size (Cohen’s d=0.2) for a continuous outcome and 
80% power.20 Allowing for 20% attrition,21 the sample size 
was set at 25 participants per arm.
Randomisation
Participants were randomised to the intervention or 
control group with 1:1 allocation using the Sealed Enve-
lope online randomisation service.22 This was set up by 
an independent statistician to generate blocked randomi-
sation with varying block lengths, stratified according to 
educational level. The researcher performing the rando-
misation was unable to access the allocation codes. Given 
the nature of the intervention, participant blinding was 
not possible.
Intervention group
Intervention group participants received usual care 
and the OA peer mentorship intervention. Usual care 
consisted of information resources (an OA booklet from 
Arthritis Research UK (now Versus Arthritis)23 and a 
handout about local services/support groups/activities). 
The intervention group participants received the infor-
mation resources during their initial mentorship session 
and were offered the opportunity to discuss the resources 
with their peer mentor.
Control group
Control group participants received usual care only. The 
control group participants received the information 
resources during their baseline researcher visit and were 
offered the opportunity to discuss the resources with the 
researcher.
OA peer mentorship intervention
Intervention development
The OA peer mentorship intervention was developed 
in two stages. The first stage included a rapid review of 
published primary studies investigating one- to- one peer 
support interventions. The review aimed to identify: the 
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support interventions; training and support approaches 
for peer mentors involved in intervention delivery; 
and challenges of developing and implementing face- 
to- face peer support to improve self- management of 
long- term conditions. Using Medline, CINAHL and 
PsycInfo, a search of the literature between 2007 and 
2018 was undertaken using the terms and synonyms 
‘peer support’, ‘long term condition’ and ‘intervention’. 
Thirteen papers were included.16 24–35 The findings high-
lighted the importance of encouraging a person- centred 
approach and retaining flexibility within the peer 
mentorship sessions. There was little information about 
‘matching’ the mentee with the peer mentor, although 
some studies based this on factors such as gender and 
age. There were issues around recruitment of peer 
mentors and a need to provide support and guidance to 
peer mentors throughout the intervention.
A preliminary version of the OA peer mentorship inter-
vention was developed based on the rapid review findings 
and the following sources:
 ► Guidelines on self- management and OA from organ-
isations such as the UK National Institute for Health 
and Care Excellence and the UK charity Versus 
Arthritis.
 ► The ‘Staying Connected Programme’: an arthritis 
self- management programme previously run by 
Arthritis Care Northern Ireland (now Versus Arthritis 
Northern Ireland).36
 ► Input from project team members, including a 
consultant rheumatologist, a health psychologist 
and a physiotherapist specialising in activity pacing/
chronic pain management.
The above- mentioned sources were also used to develop 
a draft peer mentor educational resource pack. The pack 
was designed to supplement peer mentor training sessions 
and be used a resource during mentorship sessions. The 
pack included a range of handouts that peer mentors 
could give to participants.
The second stage of the development process consisted 
of expert review sessions conducted with the following key 
stakeholders: study patient and public involvement (PPI) 
members (n=2); other older individuals with OA (n=5); 
health professionals (n=4); voluntary/community organ-
isation representatives (n=4); and researchers (n=2). 
Review sessions were conducted face to face (group, 
paired or individual meetings), via telephone or via 
email. The stakeholders were provided with information 
about the provisional OA peer mentorship intervention 
and a copy of the draft educational pack. Stakeholders’ 
opinions of these were assessed using a pro forma.
Key refinements made based on the expert review 
sessions included:
 ► Peer mentors were encouraged not to cover too many 
topics in the first mentorship session to allow more 
time for developing rapport and managing partici-
pant expectations.
 ► Participants were provided with notebooks for 
recording goals, reflections and additional notes.
 ► The language used in the educational pack was 
simplified.
 ► Additional infographic handouts and further infor-
mation on falls, local authority services and emotional 
well- being were added to the educational resource 
pack.
Finalised intervention
The finalised OA peer mentorship intervention aimed 
to improve participants’ health outcomes through 
increasing their engagement with self- management 
behaviours. Figure 1 presents a logic model of the inter-
vention, including the proposed mechanisms of action. 
The intervention involved up to eight 1- hour self- 
management support sessions delivered by a trained peer 
mentor. During the sessions, the peer mentor provided 
guided support that incorporated multiple behaviour 
change techniques (BCTs) and covered a combination of 
core and optional topics (figure 1). In line with a person- 
centred approach, the implementation of BCTs and 
the choice and order of topics covered was flexible and 
participant led. However, peer mentors were encouraged 
to cover all core topics at least once and set/review goals 
with the participant weekly. Online supplemental table 3 
provides examples of the implementation of the key BCTs 
employed.
The peer mentorship sessions took place approximately 
weekly in the participant’s home or another private loca-
tion of their choice. A person- centred approach was 
emphasised throughout.37 38 Therefore, the number of 
sessions and scheduling were flexible.
The volunteer coordinator attended the start of each 
initial session to introduce the participant and peer 
mentor, remind them of the trial and intervention aims 
and answer questions. The remainder of the initial session 
and all subsequent sessions were undertaken by the 
mentor alone. The volunteer coordinator contacted the 
participant and peer mentor following the initial session 
to check they were happy to continue with subsequent 
sessions with their mentorship match. Peer mentors 
completed a ‘session summary’ in writing following each 
session, detailing the topics covered during that session, 
any challenges encountered and their reflections on the 
progress made.
Peer mentor eligibility and recruitment
Peer mentors were trained volunteers aged ≥50 years old 
with hip and/or knee OA who were able to travel inde-
pendently. Multiple approaches were used to recruit peer 
mentors, including printed/social media advertisements 
and sharing trial information at local support/activity 
groups.
Potential peer mentors were asked to complete an 
application form, supply two references and take part 
in a telephone interview with the volunteer coordinator. 
Those assessed as suitable were invited to attend a compul-
sory 2- day training event. Prior to being matched with a 
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enhanced Disclosure and Barring Service (criminal 
record) checks39 for safeguarding purposes.
Peer mentor training and matching
Three training events were held due to varying peer 
mentor availability and staggering of the mentor recruit-
ment, which meant it was not possible to train all mentors 
in one event. The first training event was provided by 
two external facilitators from Arthritis Care Northern 
Ireland and a trial team member (physiotherapist special-
ising in activity pacing/chronic pain management). 
The remaining events were provided by three trial team 
members (volunteer coordinator, the physiotherapist who 
facilitated the first training event and another musculo-
skeletal physiotherapist). Feedback from the first event 
was used to refine the content/delivery of the subsequent 
events.
The training events involved presentations and inter-
active activities covering OA self- management topics, 
mentorship skills and the practicalities of the peer mentor 
role (online supplemental table 4).
Participant/mentor matching was undertaken by the 
volunteer coordinator and the researcher who completed 
the baseline researcher visit. The initial intention was to 
base matching on location, gender preference, age and 
OA site(s). However, due to peer mentors’ preferences 
and discrepancies in the availability of intervention group 
participants and trained peer mentors, these criteria were 
relaxed.
Data collection and analysis
Feasibility outcomes
This trial’s primary focus was on assessing the feasibility 
outcomes specified in table 1. Four associated success 
criteria for proceeding to a definitive RCT were prespeci-
fied based on relevant guidance40 (table 1).
Patient-reported outcomes
Patient- reported outcomes were assessed using paper self- 
report questionnaires administered at baseline, 8 weeks 
and 6 months. The baseline questionnaires were admin-
istered by a researcher or the volunteer coordinator. The 
majority of baseline questionnaires were administered 
after the participant had been informed of their group 
allocation. This approach was chosen due to the fluctu-
ating availability of trained peer mentors. This meant 
there was sometimes a delay between participants being 
allocated to the intervention group and being able to 
commence their mentorship sessions. Therefore, most 
intervention group participants completed the baseline 
questionnaire with the volunteer coordinator immedi-
ately prior to their initial mentorship session to avoid a 
Figure 1 OA peer mentorship intervention logic model. aBehaviour change techniques are coded using the Behaviour Change 
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delay between completion of the baseline questionnaire 
and commencement of their mentorship sessions.
The 8- week and 6- month questionnaires were admin-
istered and returned via post. Non- responders were 
followed up with a second questionnaire posting 2 weeks 
later and a telephone call 4 weeks later.
The questionnaires covered participants’ sociodemo-
graphic and clinical characteristics and included validated 
tools assessing the biomedical/psychosocial outcomes 
specified below.
Provisional primary outcome measure
 ► Revised 12- item Partners in Health (PIH) Scale: 
12- item scale that assesses chronic condition self- 
management.41 Each item is scored on a 9- point 
Likert scale (0–8). Scores are summed to give a total 
score (0–96). Higher scores indicate higher self- 
management knowledge/behaviours.
Provisional secondary outcome measures
 ► Multidimensional Scale of Perceived Social Support 
(MSPSS): 12- item scale that assesses perceived 
social support from a significant other, family and 
friends.42 Each item is scored on a 7- point Likert 
scale (1–7), and the mean for all items is calculated. 
Higher scores indicate greater perceived social 
support.
 ► Western Ontario and McMaster’s University Osteoar-
thritis Index Likert version (WOMAC 3.1): 24- item 
disease- specific scale with three subscales that assess 
pain (5 items), stiffness (2 items) and physical func-
tion (17 items).43 Each item is scored on a 5- point 
Likert scale (0–4). Scores are summed to give a total 
score (0–96) and subscale scores (pain: 1–20; stiffness: 
0–8; physical function: 0–68). Higher scores indicate 
more severe problems.
 ► Eight- item Arthritis Self- Efficacy Scale English 
version: 8- item scale that assesses self- efficacy for 
managing arthritis symptoms.44–46 Each item is scored 
on a 10- point Likert scale (1–10), and the mean for 
all items is calculated. Higher scores indicate greater 
self- efficacy.
 ► Hospital Anxiety and Depression Scale (HADS): 
14- item scale with two subscales that assess symptoms 
of anxiety (7 items) and depression (7 items).47 Each 
item is scored on a 4- point Likert scale (0–3). Scores 
are summed to give a total score (0–42) and subscale 
Table 1 Feasibility outcomes and success criteria for proceeding to a definitive randomised controlled trial
Feasibility outcome Details of feasibility outcome Success criterion
Peer mentor recruitment rate Number of peer mentors trained divided by the number 
individuals who were eligible for the peer mentor role
1. Demonstration that the 
intervention can be delivered in 
practice and is acceptable to 
participants and peer mentors*
Peer mentor attrition rate Number of peer mentors who were not matched with a 
participant divided by the number of peer mentors trained
Intervention completion rate Number of participants who completed at least three 
peer mentorship sessions divided by the number of 
participants who commenced the intervention
Participant recruitment rate Number of participants randomised divided by the 
number of individuals who were eligible to participate
2. ≥60% of eligible individuals 
recruited
Attrition rate overall and in 
each group
Number of participants who did not complete the 6- month 
questionnaire divided by the number of participants 
randomised
3. <20% participant attrition with no 
evidence of attrition bias
Sample size required for a 
definitive RCT
Sample size calculation using the feasibility trial PIH scale 
scores assuming: 5% significance level; minimum power 
of 0.8; and 1:1 allocation ratio. The PIH scale scores 
were used because the PIH scale was chosen as the 
provisional primary outcome measure.
4. Calculation of a sample size that is 
achievable in a main trial
Questionnaire completion 
rate
Number of questionnaires completed divided by the 
number of participants provided with the questionnaires
None specified for these feasibility 
outcomes
Intervention fidelity Content analysis of the mentors’ session summaries
Cost of delivering the mentor 
training event
Estimation based on the events delivered by the trial team 
members accounting for: staff salary, national insurance 
and pension contributions; resources; refreshments; and 
peer mentor travel expenses; but not venue hire, estates 
and indirect costs
Cost of delivering the 
intervention
Estimation based on the volunteer coordinator and peer 
mentor costs, excluding the training costs
*No minimum/maximum rates were prespecified as acceptable for this success criterion.
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scores (0–21). Higher scores indicate more severe 
symptoms.
 ► EQ-5D- 5L: Descriptive system and visual analogue 
scale (VAS) that assess general health status.48 49 The 
descriptive system includes five dimensions, each 
of which has five response levels. Each response is 
converted to a single- digit number. The numbers for 
each of the five dimensions can then be converted to a 
single index value anchored at 0 (a state equivalent to 
dead) and 1 (full health). The VAS consists of a single 
score on a scale from 0 (worst health imaginable) to 
100 (best health imaginable).
The 8- week and 6- month questionnaires included 
sections on healthcare and community resource use, 
adapted from the Client Services Receipt Inventory.50
Missing data were addressed in line with guidance for 
the relevant outcome measurement tool. The quantita-
tive questionnaire responses were analysed using STATA 
(V.15). Given the trial was not powered to detect statisti-
cally significant differences, the analyses were predomi-
nantly descriptive. However, exploratory analyses of the 
outcome measure data and healthcare resource use data 
were performed. The outcome scores were tested for 
normality at the 5% significance level.51 Between- group 
comparisons were made using analysis of covariance 
models and, where the scores were significantly skewed, 
quantile regression models were used.52
Patient and public involvement
PPI played a key role in this trial as follows:
 ► During the trial development stage, six individuals 
with OA were consulted for research ideas, and eight 
members of a local musculoskeletal PPI group partic-
ipated in a group discussion. These patient represent-
atives emphasised that one- to- one mentorship would 
be preferable to a group- based approach and felt the 
questionnaire burden was appropriate.
 ► Three patient representatives became ‘study PPI 
members’ and assisted with the conduct of the study, 
reviewing lay materials and finalising the dissemina-
tion plans. These PPI members were also invited to 
attend peer mentorship training sessions.
 ► Two study PPI members and five other individuals 
with OA helped refine the provisional intervention 
and educational resources through expert review 
sessions.
 ► The peer mentors were all trained volunteers with hip 
and/or knee OA. Peer mentors were encouraged to 
give regular informal feedback about their involve-
ment in the trial, as well as being invited to participate 
in a nested qualitative study (reported elsewhere).
RESULTS
Feasibility outcomes
Participant flow and intervention completion
Participant recruitment took place between 22 November 
2018 and 30 May 2019. The final questionnaire was 
completed on the 16 February 2020. At least 345 indi-
viduals were approached (figure 2). Ninety- six individ-
uals were screened, of whom 65 were eligible. The most 
common reason for ineligibility was being listed for joint 
replacement (n=8). Fifty individuals were randomised. 
Therefore, the participant recruitment rate was 77%. 
The most common reason for declining participation was 
insufficient time/other commitments (n=7). Most partic-
ipants were recruited through the primary care physio-
therapy department (n=44).
One intervention group participant withdrew due to ill- 
health prior to completing the baseline questionnaire and 
commencing the intervention. Of the 24 participants who 
commenced the intervention, 20 completed at least three 
mentorship sessions (figure 2). The intervention comple-
tion rate was therefore 83%. Reasons for discontinuing 
the intervention largely related to participants feeling the 
intervention was not relevant to their needs, for example, 
due to having mild OA symptoms and/or feeling they 
did not require additional self- management support. 
The mean number of mentorship sessions received was 
5.79 (SD=2.25; median=7). No harms/unintended effects 
related to the intervention occurred.
One intervention participant who discontinued the 
intervention after two mentorship sessions withdrew 
(no reason provided). One additional intervention 
participant who discontinued the intervention after two 
mentorship sessions did not complete the follow- up 
questionnaires. One control group participant did not 
complete the follow- up questionnaires. A family member 
of this control group participant returned his 6- month 
questionnaire indicating he had died. The attrition rates 
were therefore: 8% overall, 12% in the intervention 
group and 4% in the control group.
Questionnaire completion
Among the participants who were provided with the 
questionnaires, the questionnaire completion rate for 
both groups was 100% at baseline and 96% at 8 weeks 
and 6 months (figure 2). Minor issues were noted with 
the resource use sections. Some participants duplicated 
details, for example, by recording the same physiotherapy 
appointments under ‘Hospital services’ and ‘Services 
outside the hospital’. Additionally, the ‘day activities’ 
reported by participants largely related to their hobbies, 
such as yoga and dancing, rather than social/community 
support activities.
Peer mentor flow and characteristics
Peer mentor recruitment took place between May 2018 
and January 2019. Thirty- two individuals enquired about 
the role, of whom 21 were eligible (online supplemental 
figure 1). Five eligible individuals were unable to attend 
the training events, one withdrew due to ill- health and 
15 were trained. The peer mentor recruitment rate was 
therefore 71%. Five trained mentors withdrew prior to 
being matched, most commonly due to ill- health (n=3). 
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most successful peer mentor recruitment approach was 
a local community magazine advertisement, which led to 
recruitment of five active peer mentors.
Nine active peer mentors were female and one was 
male. Their mean age was 68 years old (SD=5.5; range=57–
75). All had been living with hip and/or knee OA for at 
least 3 years. Nine were retired, although three had only 
recently stopped work, and one worked full- time. Each 
active peer mentor supported between one and four 
participants (online supplemental table 1).
Session summary data
The session summaries indicated the following topics 
were covered by almost all participant/mentor dyads and 
were the most frequently covered overall: learning about 
OA; goal setting; pacing; muscle strengthening; and pain 
management. In addition, getting active and eating well 
were frequently covered.
The least frequently covered topics were: getting 
connected with friends/services; and effective commu-
nication. Correspondingly, these topics were covered by 
Figure 2 Participant flow diagram. aMinimum number of individuals approached/excluded. Additional individuals may have 
been approached/excluded because the number of individuals approached through physiotherapy clinics was not recorded to 
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only six and eight dyads, respectively. Positive thinking 
and sleep quality were also rarely covered.
Intervention costs
The estimated cost of delivering the training event to five 
peer mentors (mean number of mentors per event) was 
£239 per mentor (online supplemental table 5). The esti-
mated cost of delivering the intervention based on the 
mean number of 5.79 mentorship sessions was £274 per 
participant (online supplemental table 6).
Sample size calculation
Based on the assumptions stated in table 1, between- 
groups variance and within- groups variance of the PIH 
scale at 6 months of 369.1 and 6237.1, respectively, and 
detecting a difference in the PIH scale of 4.4 (effect size 
at 6 months), the sample size required for a definitive 
RCT was calculated as 136 participants (68 per group). 
Retaining the same attrition rate as for the feasibility trial 




Table 2 provides a summary of participants’ baseline 
sociodemographic and clinical characteristics. Additional 
details are available in online supplemental table 7.
Provisional primary outcome
The mean PIH scores at baseline were 73.9 and 76.5 
for the intervention and control groups, respectively 
(table 3). After 8 weeks, the mean PIH score improved 
in the intervention group (mean change=2.6; SD=13.2) 
and deteriorated in the control group (mean change= 
−7; SD=12.3). Thus, the intervention group participants 
appeared to have better self- management knowledge/
behaviours than the control group participants at 8 weeks 
(effect size=8.3; 95% CI 2.2 to 14.4) (table 4). At 6 months, 
the intervention group’s mean PIH score was similar to 
the group’s score at 8 weeks, while the control group’s 
mean PIH score increased but remained lower than at 
baseline. Overall, the intervention group had higher 
PIH scores than the control group after 6 months (effect 
size=4.4; 95% CI −2.8 to 11.6) (table 4).
Provisional secondary outcomes
There were no significant between- group differences for 
any of the secondary outcomes at 8 weeks or 6 months. 
However, the mean WOMAC and HADS scores were 
lower in the intervention group than the control group at 
baseline and both follow- up time- points.
Resource use
Healthcare resource use between baseline and 6 months 
was largely similar between groups. The main differences 
Table 2 Participant baseline characteristics
Characteristics Intervention n=24 Control n=25
Age in years, mean (SD) 70.0 (8.6) 69.3 (8.1)
Men, n (%) 10 (41.7) 4 (16.0)
Ethnicity, white, n (%) 21 (87.5) 24 (96.0)
Further education*, n (%) 15 (62.5) 15 (60.0)
Employed, n (%) 7 (29.2) 5 (20.0)
Retired, n (%) 17 (70.8) 20 (80.0)
Body mass index in kg/m2, mean (SD) 27.5 (6.3) 28.5 (5.5)
Duration of arthritis diagnosis in years, mean (SD) 4.7 (5.2) 5.3 (6.2)
At least one hip affected by arthritis, n (%) 14 (58.3) 13 (52.0)
At least one knee affected by arthritis, n (%) 22 (91.7) 21 (84.0)
VAS for current pain due hip/knee arthritis, mean (SD) 52.8 (26.8) 48.6 (26.3)
VAS for ability to cope with/manage arthritis in general, mean (SD) 66.2 (21.8) 64.4 (21.8)
Number of joints affected by pain for >6 weeks in the last 3 months, median (IRQ) 5 (4) 3 (3)
Number of comorbidities†, n (%)
0 8 (33.3) 6 (24.0)
1 5 (20.8) 10 (40.0)
2 5 (20.8) 3 (12.0)
≥3 6 (25.0) 6 (24.0)
*Further education was defined as any formal education undertaken once the participant was aged over 16 years old.
†Comorbidities include: diabetes; asthma; bronchitis; gastrointestinal problems; angina/heart problems; high blood pressure; depression; and 
anxiety.
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were more overnight hospital stays in the control group 
(mean difference between groups=−0.91; 95% CI 
−1.78 to −0.04), and more GP practice nurse visits in 
the intervention group (mean difference between 
groups=0.93; 95% CI 0.15 to 1.71) (online supplemental 
table 8). No participants reported attending a day centre. 
Table 3 Outcome measurement scores at baseline, 8 weeks and 6 months
Outcome measure











PIH scale 73.9 (16.3) 76.5 (14.3) 76.5 (14.5) 69.5 (10.6) 76.0 (13.4) 73.0 (15.0)
MSPSS 5.3 (1.1) 5.7 (0.98) 4.9 (1.6) 5.2 (1.6) 4.9 (1.3) 5.4 (1.4)
WOMAC total* 32.6 (18.8) 41.9 (19.5) 34.0 (17.8) 43.5 (19.4) 34.7 (18.5) 41.3 (17.8)
WOMAC pain* 6.8 (4.5) 9 .0 (4.2) 7.5 (3.9) 9.6 (4.1) 7.7 (4.0) 8.9 (3.2)
WOMAC stiffness* 3.7 (1.6) 4.3 (1.9) 3.3 (1.3) 4.3 (1.6) 3.4 (1.3) 4.0 (1.7)
WOMAC function* 22.1 (14.0) 28.5 (14.6) 23.2 (13.2) 29.6 (15.3) 23.6 (14.8) 28.3 (13.5)
ASES-8 6.0 (1.9) 5.9 (1.7) 5.5 (2.2) 6.5 (2.4) 6.3 (1.6) 5.3 (2.5)
HADS total* 9.4 (4.4) 11.3 (7.2) 10.5 (5.7) 12.7 (8.3) 10.7 (6.2) 12.8 (8.4)
HADS anxiety* 5.3 (3.1) 6.7 (4.3) 6.3 (3.4) 7.3 (4.8) 5.9 (3.9) 7.5 (4.9)
HADS depression* 4.1 (2.0) 4.6 (3.6) 4.3 (3.1) 5.4 (4.0) 4.8 (2.7) 5.3 (4.0)
EQ- 5D- 5L index‡, † 0.723 (0.139) 0.645 (0.170) 0.691 (0.099) 0.647 (0.249) 0.687 (0.088) 0.647 (0.183)
EQ- 5D- 5L VAS† 70 (15.0) 75 (20.0) 70 (25.0) 70 (22.5) 75 (20.0) 70 (23.5)
*Higher scores indicate more severe problems.
†Median (IQR).
‡EQ- 5D- 5L index value control group n=23 due to missing data.
ASES-8, 8- item Arthritis Self- Efficacy Scale English version; HADS, Hospital Anxiety and Depression Scale; MSPSS, Multidimensional Scale 
of Perceived Social Support; PIH scale, revised 12- item Partners in Health Scale; VAS, Visual Analogue Scale; WOMAC, Likert version of the 
Western Ontario and McMaster’s University Osteoarthritis Index.
Table 4 Outcome measurements score changes and effect of the intervention at 8 weeks and 6 months
Outcome measure
Changes at 8 weeks Effect size at 8 
weeks, mean
(95% CI)*
Changes at 6 months Effect size at 6 
months, mean
(95% CI)*Intervention Control Intervention Control
PIH scale 2.6 (13.2) −7.0 (12.3) 8.3 (2.2 to 14.4) 2.1 (10.6) −3.5 (16.6) 4.4 (−2.8 to 11.6)
MSPSS −0.28 (1.4)† −0.25 (1.2)† 0.0 (−0.80 to 0.80)‡ −0.42 (0.93)† −0.06 (0.6)† −0.40 (−0.84 to 0.03)‡
WOMAC total§ 3.0 (19)† 5.0 (22)† −2.6 (−10.2 to 4.9)‡ 2.1 (8.6) −0.59 (19.1) −0.65 (−8.9 to 7.6)
WOMAC pain§ 0.64 (2.6) 0.63 (3.7) −0.75 (−2.5 to 1.0) 0.91 (2.4) −0.09 (3.8) 0.06 (−1.6 to 1.7)
WOMAC stiffness§ −0.36 (1.5) −0.04 (1.1) −0.59 (−1.3 to 0.08) −0.27 (1.8) −0.29 (1.2) −0.31 (−1.1 to 0.46)
WOMAC function§ 1.1 (7.8) 1.0 (10.4) −1.3 (−6.7 to 4.1) 1.5 (7.8) −0.21 (15.4) −0.8 (−7.7 to 6.0)
ASES-8 0.48 (1.6) −0.04 (2.25) 0.64 (−0.51 to 1.8) 0.69 (3.0)† 0.0 (3.3)† 0.34 (−1.3 to 1.9)‡
HADS total§ 1.12 (3.8) 1.38 (4.5) −0.27 (−2.8 to 2.3) 1.33 (3.4) 1.5 (4.3) −0.01 (−2.4 to 2.4)
HADS anxiety§ 0.95 (2.8) 0.58 (2.1) 0.26 (−1.2 to 1.7) 0.59 (2.4) 0.79 (2.6) −0.23 (−1.8 to 1.3)
HADS depression§ 0.20 (2.4) 0.79 (3.4) −0.74 (−2.5 to 1.0) 0.74 (1.6) 0.67 (2.5) 0.03 (−1.3 to 1.3)
EQ- 5D- 5L index¶ −0.057 (0.20) 0 (0.12) −0.06 (−0.18 to 0.06) −0.053 (0.14) 0 (0.19) −0.04 (−0.12 to 0.04)
EQ- 5D- 5L VAS −2.5 (20)† 0 (10)† 0 (−10.8 to 10.8)‡ 0 (20)† −5 (21)† 6.7 (−4.6 to 18.0)‡
*Analysis of covariance models adjusted for baseline outcomes.
†Median (IQR).
‡Median (95% CIs).
§Higher scores indicate more severe problems.
¶EQ- 5D- 5L index value control group n=23 due to missing data.
ASES-8, 8- item Arthritis Self- Efficacy Scale English version; HADS, Hospital Anxiety and Depression Scale; MSPSS, Multidimensional 
Scale of Perceived Social Support; PIH scale, revised 12- item Partners in Health Scale; WOMAC, Likert version of the Western Ontario and 
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Two intervention group participants and four control 
group participants reported receiving help with daily 
activities.
DISCUSSION
This feasibility trial aimed to develop and trial a peer 
mentorship intervention to improve OA self- management. 
All four prespecified success criteria for proceeding to a 
definitive RCT (table 1) were achieved. The peer mentor 
recruitment rate (71%), peer mentor attrition rate (33%) 
and intervention completion rate (83%) all compare 
favourably with previous peer mentorship studies.16 32 53 54 
This suggests the OA peer mentorship intervention can be 
delivered in practice and is acceptable to participants and 
peer mentors. However, some participants discontinued 
the intervention due to having mild OA symptoms and 
feeling they did not need self- management support. This 
could be overcome by specifying a minimum symptom 
severity threshold and/or a maximum arthritis- related 
self- efficacy threshold in the eligibility criteria to prevent 
inclusion of individuals who have mild symptoms and/or 
already feel confident about managing their symptoms.
The participant recruitment rate was 77% and hence 
well above the prespecified minimum threshold of 60%. 
However, this recruitment rate did not account for indi-
viduals lost prior to screening. The overall participant 
attrition rate at 6 months was 8% and hence well below the 
prespecified maximum threshold of 20%. This suggests 
that additional strategies to improve participant recruit-
ment and retention would not be needed for a future 
RCT. Allowing for 20% attrition, the sample size required 
for a definitive RCT was calculated as 170 participants (85 
per group). Assuming each peer mentor supports two 
participants, this would require 43 mentors. This target 
RCT sample size is achievable. However, only 10 active 
peer mentors were recruited during this trial. Additional 
strategies would therefore be needed to recruit sufficient 
mentors. These could include using multiple recruitment 
sites across a wider geographical area, recruiting mentors 
over a longer time- period, using snowballing recruitment 
with previously trained peer mentors and optimising 
recruitment through media outlets, such as magazine 
advertisements.
The findings for the remaining feasibility outcomes 
were also encouraging. The questionnaire completion 
rates were consistently high (96%–100%). However, 
minor modifications to the resource use sections would 
be beneficial to avoid participants duplicating details/
reporting unnecessary details. The session summary data 
indicated intervention fidelity was good overall, with 
most participant/mentor dyads covering four of the five 
core topics. The remaining core topic, getting connected 
with friends/services, was only covered by six dyads. 
This may be because the participants already had good 
social support networks, as suggested by their relatively 
high MSPSS scores. Additionally, most dyads covered the 
optional topic of pain management. Therefore, changing 
getting connected to an optional topic and pain manage-
ment to a core topic warrants consideration.
The estimated costs of training peer mentors and deliv-
ering the intervention were £239 per mentor and £274 
per participant respectively. The training costs would 
have been lower if fewer training events had been run 
with more mentors per event. This was not possible due 
to varying peer mentor availability and staggering of the 
mentor recruitment. A similar issue was noted in a study 
of peer mentorship for people with advanced cancer54 
and would need accounting for in a future RCT.
This trial included exploratory analyses of the impact 
of the OA peer mentorship intervention on patient- 
reported outcomes. These analyses provide a prelim-
inary insight into the potential effectiveness of the 
intervention. However, the results must be interpreted 
cautiously because the present trial was not powered to 
detect statistically significant differences. The exploratory 
analyses suggest the OA peer mentorship intervention 
may improve self- management knowledge/behaviours 
(table 4). However, no significant effects of the OA peer 
mentorship intervention on other outcomes, such as pain 
and arthritis- related self- efficacy, were observed in the 
present trial.
A Cochrane review identified low to moderate 
quality evidence indicating self- management educa-
tion programmes for people with OA do not result in 
any clinically meaningful benefits.55 Despite this, the 
authors concluded that trials investigating alterna-
tive self- management support approaches, particularly 
those involving tailored support, are warranted. One 
such approach is the Staying Connected Programme, a 
tailored one- to- one 8- week self- management programme 
delivered by trained volunteers.36 A recent quasi- 
experimental study identified significant improvements 
in pain and arthritis- related self- efficacy among individ-
uals with arthritis who participated in this programme.36 
The Staying Connected Programme volunteers were 
not required to have an arthritis diagnosis, despite peer 
support being recognised as a valuable approach for 
supporting self- management.11 12 In addition, the Staying 
Connected Programme aimed to support individuals 
with various types of arthritis and other long- term condi-
tions.36 The present trial’s intervention therefore aimed 
to replicate some key elements of the Staying Connected 
Programme while also incorporating peer support and 
being tailored specifically to the needs of people with OA. 
Although there are disparities between the findings of 
the present trial and the Staying Connected Programme 
study, neither was an adequately powered RCT. Future 
work is therefore required to determine the effectiveness 
of both the present trial’s OA peer mentorship interven-
tion and the Staying Connected Programme.
In addition to drawing on the Staying Connected 
Programme, the development of the OA peer mentor-
ship intervention incorporated multiple other sources 
and an expert review with key stakeholders. This 
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the intervention is feasible, acceptable and focused on 
the needs of individuals with OA. The substantial invest-
ment in the development process will also maximise the 
chances of the intervention proving effective during a 
future definitive RCT. A potential limitation is that the 
development process was not based on a single behaviour 
change theory or theoretical framework. However, the 
broad range of sources considered and input from multi-
disciplinary experts helped ensure that the intervention 
has a sound theoretical basis (figure 1). In particular, the 
focus on enhancing self- efficacy is consistent with other 
peer support interventions aimed at improving chronic 
condition self- management.24 32 56 57
This trial also presents additional limitations. Notably, 
88% of participants were recruited through a physio-
therapy service and hence had already received some self- 
management support. This could be addressed through 
using alternative recruitment sites, such as GP practices. 
Furthermore, the majority of participants were older, 
white, well- educated females, and a Cochrane review 
identified that the impact of self- management educa-
tion programmes for OA may vary between Caucasian, 
educated females and other subgroups.55 Additionally, 
peer support interventions may be most effective among 
the ‘hardly reached’, such as individuals with lower 
education levels.58 Targeting the OA peer mentorship 
intervention to specific subgroups could therefore be 
valuable. Participants and peer mentors’ experiences 
of the OA peer mentorship intervention were explored 
through a nested qualitative study (reported elsewhere). 
However, the impact of providing the intervention on the 
peer mentors was not quantitatively assessed. This is an 
important consideration because providing peer mentor-
ship may have positive and/or negative effects on peer 
mentors.11 26 Another limitation of the present trial was 
that most participants were aware of their group alloca-
tion when completing the baseline questionnaire, which 
may have influenced their questionnaire responses.59 
This could be overcome in a future definitive RCT by 
ensuring a greater number of trained peer mentors are 
available and/or administering the baseline question-
naire by post/online.
In conclusion, this trial’s findings suggest peer mentor-
ship is a feasible, acceptable and promising approach 
for improving OA self- management. Further investiga-
tion of the OA peer mentorship intervention is there-
fore warranted. However, minor modifications to the 
intervention and trial procedures should be considered, 
particularly regarding the participant and peer mentor 
recruitment procedures.
Twitter Anna M Anderson @_Anna_Anderson
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Supplementary Table 1: CONSORT 2010 checklist of information to include 
when reporting a pilot or feasibility randomised trial in a journal or conference 
abstract 
 
Item Description Reported on 
line number 
Title  Identification of study as randomised pilot or feasibility 
trial 
2 
Authors Contact details for the corresponding author 15-17 
Trial design Description of pilot trial design (eg, parallel, cluster) 28 
Methods 
Participants Eligibility criteria for participants and the settings where 
the pilot trial was conducted 
29-30, 33 
Interventions Interventions intended for each group 32-35 
Objective Specific objectives of the pilot trial 25-27 
Outcome Prespecified assessment or measurement to address 
the pilot trial objectives 
36-40 
Randomisation How participants were allocated to interventions 32 
Blinding 
(masking) 
Whether or not participants, care givers, and those 






Number of participants screened and randomised to 
each group for the pilot trial objectives 
41-42 
Recruitment Trial status N/Aa 
Numbers 
analysed 
Number of participants analysed in each group for the 
pilot objectives 
42-45 
Outcome Results for the pilot objectives, including any 
expressions of uncertainty 
41-48 
Harms Important adverse events or side effects 45-46 
Conclusions General interpretation of the results of pilot trial and 




Registration number for pilot trial and name of trial 
register 
53 
Funding Source of funding for pilot trial 54 
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N/A, Not applicable 
a Not applicable as item is only applicable to conference abstracts. 
 
Checklist from: Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 
statement: extension to randomised pilot and feasibility trials. BMJ 2016;355:i5239. 
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Supplementary Table 2: CONSORT 2010 checklist of information to include when reporting a pilot or feasibility trial 
 
Section/Topic Item No Checklist item 
Reported on 
page No 
Title and abstract 
 1a Identification as a pilot or feasibility randomised trial in the title 1 




2a Scientific background and explanation of rationale for future definitive trial, and reasons 
for randomised pilot trial 
4-5 
2b Specific objectives or research questions for pilot trial 5 
Methods 
Trial design 3a Description of pilot trial design (such as parallel, factorial) including allocation ratio 5 
3b Important changes to methods after pilot trial commencement (such as eligibility 
criteria), with reasons 
13 
Participants 4a Eligibility criteria for participants 6 
4b Settings and locations where the data were collected 6, 11, 15 
 4c How participants were identified and consented 6 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how 
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Outcomes 6a Completely defined prespecified assessments or measurements to address each pilot 
trial objective specified in 2b, including how and when they were assessed 
13-17 
6b Any changes to pilot trial assessments or measurements after the pilot trial commenced, 
with reasons 
N/A 
 6c If applicable, prespecified criteria used to judge whether, or how, to proceed with future 
definitive trial 
14 
Sample size 7a Rationale for numbers in the pilot trial 7 




8a Method used to generate the random allocation sequence 7 




9 Mechanism used to implement the random allocation sequence (such as sequentially 
numbered containers), describing any steps taken to conceal the sequence until 
interventions were assigned 
7 
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who 
assigned participants to interventions 
6-7 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, 
care providers, those assessing outcomes) and how 
N/A 
11b If relevant, description of the similarity of interventions N/A 
Statistical methods 12 Methods used to address each pilot trial objective whether qualitative or quantitative 14, 17-18 
Results 
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Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were approached and/or assessed for 




13b For each group, losses and exclusions after randomisation, together with reasons 20 
Figure 2 
Recruitment 14a Dates defining the periods of recruitment and follow-up 5, 19 
14b Why the pilot trial ended or was stopped N/A 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 23 
Supplementary 
table 7 
Numbers analysed 16 For each objective, number of participants (denominator) included in each analysis. If 




17 For each objective, results including expressions of uncertainty (such as 95% 
confidence interval) for any estimates. If relevant, these results should be by 
randomised group 
19-28 
Ancillary analyses 18 Results of any other analyses performed that could be used to inform the future 
definitive trial 
N/A 
Harms 19 All important harms or unintended effects in each group  N/A 
 19a If relevant, other important unintended consequences N/A 
Discussion 
Limitations 20 Pilot trial limitations, addressing sources of potential bias and remaining uncertainty 
about feasibility 
29-33 
Generalisability 21 Generalisability (applicability) of pilot trial methods and findings to future definitive trial 
and other studies 
32 
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Interpretation 22 Interpretation consistent with pilot trial objectives and findings, balancing potential 
benefits and harms, and considering other relevant evidence 
28-33 
 22a Implications for progression from pilot to future definitive trial, including any proposed 
amendments 
29-30, 32-33 
Other information  
Registration 23 Registration number for pilot trial and name of trial registry 5 
Protocol 24 Where the pilot trial protocol can be accessed, if available 35 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 34 




Checklist from: Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to randomised pilot and 
feasibility trials. BMJ 2016;355:i5239. 
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Supplementary Table 3: Key behaviour change techniques included in the 
osteoarthritis peer mentorship intervention 
  
Behaviour change techniquea Example of implementation 
1.1 Goal setting (behaviour) The peer mentor supports the participant to set a goal 
of meeting a friend for coffee twice weekly.   
1.2 Problem solving The peer mentor supports the participant to analyse 
barriers to pacing their activities and identify strategies 
to help overcome the barriers.  
1.4 Action planning The peer mentor supports the participant to plan when 
and where they will go cycling and how long their cycle 
rides will last. 
1.5 Review behaviour goal(s) The peer mentor and participant review the 
participant’s goal of not drinking any caffeinated drinks 
after 5.00pm and adapt it if necessary. 
2.2 Feedback on behaviour The peer mentor provides the participant with feedback 
on their strengthening exercise technique during their 
peer mentorship session. 
3.1 Social support (unspecified) The peer mentor provides information about a local 
walking football group. 
3.3 Social support (emotional) The peer mentor provides emotional support to help 
the participant to go for a walk even though they feel 
anxious about falling. 
4.1 Instruction on how to 
perform the behaviour 
The peer mentor advises the participant how to 
perform a relaxation technique. 
5.1 Information about health 
consequences 
The peer mentor explains that losing weight can help 
improve symptoms of osteoarthritis. 
5.6 Information about emotional 
consequences 
The peer mentor explains that using conscious 
breathing techniques can help people feel calmer. 
6.1 Demonstration of the 
behaviour 
The peer mentor demonstrates how to perform chair 
based exercises. 
6.2 Social comparison The peer mentor draws attention to how they are able 
to do yoga despite their osteoarthritis. 
8.1 Behavioural 
practice/rehearsal 
The peer mentor prompts the participant to practice 
being assertive in preparation for their doctor’s 
appointment. 
8.3 Habit formation The peer mentor prompts the participant to carry out an 
exercise routine in their bedroom after they have had a 
shower each morning. 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open




8.7 Graded tasks The peer mentor supports the participant to swim 20 
lengths by advising them to start with 10 lengths and 
then add an extra two lengths each week. 
9.1 Credible source The peer mentor provides communication in favour of 
eating five portions of fruit and vegetables per day.  
10.4 Social reward The peer mentor praises the participant for progressing 
towards their goal of getting up at 8.30am each 
morning. 
15.1 Verbal persuasion about 
capability 
The peer mentor tells the participant that they can do 
leg strengthening exercises safely despite their 
osteoarthritis. 
 
a Behaviour change techniques are coded using the Behaviour Change Technique 
Taxonomy version 1 from: Michie S, Richardson M, Johnston M, et al. The Behavior 
Change Technique Taxonomy (v1) of 93 hierarchically clustered techniques: building 
an international consensus for the reporting of behavior change interventions. Ann 
Behav Med 2013 Aug;46(1):81-95. doi: 10.1007/s12160-013-9486-6. 
Only key behaviour change techniques are listed. Peer mentors could incorporate 
additional behaviour change techniques as appropriate to the participant’s individual 
needs and goals.   
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Supplementary Table 4: Overview of areas covered during the peer mentor 
training event 
 
Day 1 Day 2 
 Overview of the trial and peer mentor 
role 
 Osteoarthritis key facts and self-
management topics 
 Goal setting 
 Pacing 
 Educational resource pack review 
 Exercise 
 Pain management  
 Sleep 
 Review of day 1 
 Communication 
 Professional boundaries 
 Mentoring in practice (including 
safeguarding, disclosures and 
confidentiality) 
 Visit and recording procedures 
 Trial data collection 
 Next steps 
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Supplementary Table 5: Estimated costs of delivering the two day peer mentor 
training event to five peer mentors 
 
Staff costsa  
 Hourly rateb Hours per event Cost per event 
Research Fellow (Grade 7) £32.23 7.5 £241.73 
Research Associate (Grade 6)  £26.09 15 £391.35 
Volunteer Coordinator (Grade 5)  £21.79 15 £326.85 
Total staff costs £959.93 
Peer mentor costs  
 Cost per peer mentor Cost per event 
Refreshments £18.00 £90.00 
Notebook £2.48 £12.40 
Ring binder £2.00 £10.00 
Plastic wallets £0.67 £3.33 
Printing £10.50 £52.50 
Name badge  £0.14 £0.68 
Travel expenses £13.14 £65.70 
Total peer mentor costs £46.92 £234.62 
Overall costs 
 Cost per peer mentor Cost per event 
Overall costs £238.91 £1,194.54 
 
a Staff costs were based on the events run by the trial team members. 
b Includes staff salary, National Insurance contributions and pension contributions, 
but does not include estates costs or indirect costs. 
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Supplementary Table 6: Estimated costs of delivering the OA peer mentorship 
intervention to one participant  
 
Volunteer Coordinator costs (Grade 5 hourly rate £21.79a) 
 Per single session Per 5.79 sessionsb 
Hours spent supporting mentorship 
sessions (0.5 hours per session) 
£10.90 £63.10 
Additional hours spent on matching, 
initial session and closure (4 hours) 
£15.05 £87.16 
Travel expenses for initial session £0.81 £4.72 
Total Volunteer Coordinator costs £26.76 £154.98 
Peer mentor costs  
 Per single session Per 5.79 sessionsb 
Honorarium £15 £86.88 
Travel expenses £5.53 £32.01 
Total peer mentor costs £20.53 £118.89 
Overall costs 
 Per single session Per 5.79 sessionsb 
Overall costs £47.29 £273.86 
 
a Includes staff salary, National Insurance contributions and pension contributions, 
but does not include estates costs or indirect costs. 
b 5.79 was the mean number of mentorship sessions received by participants. 
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Control           
n=25 
Marital status, n (%)   
Married 12 (50.0) 17 (68.0) 
Divorced 6 (25.0) 2 (8.0) 
Living together 0 (0.0) 1 (4.0) 
Widowed 5 (20.8) 3 (12.0) 
Single 1 (4.2) 2 (8.0) 
Current smokers, n (%) 1 (4.2) 2 (8.0) 
Areas affected by arthritis, n (%)   
Single hip 0 (0.0) 0 (0.0) 
Both hips 2 (8.3) 4 (16.0) 
Single knee 2 (8.3) 3 (12.0) 
Both knees 8 (33.3) 9 (36.0) 
Single hip and single knee 2 (8.3) 3 (12.0) 
Both hips and one knee 2 (8.3) 1 (4.0) 
Single hip and both knees 5 (20.8) 2 (8.0) 
Both hips and both knees 3 (12.5) 3 (12.0) 
Areas affected by joint pain for > 6 weeks in 
the last 3 months, n (%)   
Neck 7 (29.2) 6 (24.0) 
Shoulder (right) 7 (29.2) 6 (24.0) 
Shoulder (left) 7 (29.2) 7 (28.0) 
Elbow (right) 0 (0.0) 2 (8.0) 
Elbow (left) 0 (0.0) 2 (8.0) 
Hand (right) 9 (37.5) 6 (24.0) 
Hand (left) 9 (37.5) 5 (20.0) 
Back 6 (25.0) 11 (44.0) 
Hip (right) 10 (41.7) 10 (40.0) 
Hip (left) 10 (41.7) 10 (40.0) 
Knee (right) 19 (79.2) 16 (64.0) 
Knee (left) 19 (79.2) 20 (80.0) 
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Foot (right) 5 (20.8) 4 (16.0) 
Foot (left) 4 (16.7) 5 (16.0) 
Duration of pain in years, mean (SD) 4.7 (5.2) 5.3 (6.2) 
Currently suffering from pain, n (%) 23 (95.8) 25 (100.0) 
Frequency of paina, n (%)     
Always 7 (30.4) 11 (44.0) 
Often present 5 (21.7) 9 (36.0) 
Sometimes present 10 (43.5) 3 (20.0) 
Present very little 1 (4.4) 0 (0.0) 
Previous hip replacement, n (%) 1 (4.2) 1 (4) 
Previous knee replacement(s), n (%) 1 (4.2) 2 (8) 
Walking aid use, n (%) 8 (33.3) 7 (28.0) 
Currently using medication for pain or other 
symptoms of arthritis, n (%) 
20 (83.3) 21 (84.0) 
Currently using strong opioids, n, (%) 1 (4.2) 0 (0.0) 
Currently using over-the-counter NSAIDS, n 
(%) 
4 (16.7) 6 (24.0) 
 
NSAIDS, non-steroidal anti-inflammatory drugs; SD, standard deviation. 
a Frequency of pain intervention group n=23 because one participant reported they 
were not currently suffering from pain.  
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Supplementary Table 8: Mean resource use and mean difference between 










Mean difference (95% 
Confidence Interval) 
Inpatient length of stay (nights) 0.05 0.96 -0.91 (-1.78 to -0.04) 
Number of Outpatient 
appointments 
3.05 2.92 0.13 (-1.87 to  2.13) 
Number GP appointments 
(surgery) 
2.73 2.42 0.31 (-1.47 to  2.09) 
Number of GP visits (home) 0.00 0.17 -0.17 (-0.52 to 0.18) 
Number of GP calls (telephone) 0.59 0.67 -0.08 (-0.70 to 0.55) 
Number of GP Practice Nurse visits  1.64 0.71 0.93 (0.15 to 1.71) 
Number of District Nurse visits 0.00 0.00 0.00 
Number of Occupational Therapist 
visits 
0.09 0.21 -0.12 (-0.47 to 0.24) 
Number of Physiotherapist visits 1.36 1.96 -0.59 (-2.74 to 1.55) 
Number of Chiropodist visits 0.64 0.75 -0.11 (-0.86 to 0.63) 
Number of Pharmacist visits 2.27 1.67 0.61 (-1.04 to 2.25) 
Number of NHS Direct calls 0.18 0.13 0.06 (-0.28 to 0.39) 
Number of Walk-in Centre visits 0.41 0.13 0.28 (-0.43 to 1.00) 
Number of Counsellor visits 0.09 0.08 0.01 (-0.24 to 0.26) 
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